The Academic Glaucoma Practice of New Jersey

Albert S Khouri, MD

NJ Glaucoma

Albert S Khouri, MD

Dr Khouri is an academic glaucoma specialist serving patients in NJ and NY. As a glaucoma specialist Dr Khouri has expertise in the medical and surgical treatments of glaucoma

Dr Khouri is the Director of Glaucoma at Rutgers University and is an Associate Professor at New Jersey Medical School. He oversees Resident Education as Program Director of the only Ophthalmology training program in New Jersey. Dr Khouri also co-directs the Ophthalmology Telemedicine community outreach program.

Glaucoma Consultation

Dr Albert Khouri provides consultative glaucoma services at The Institute of Ophthalmology and Visual Science at Rutgers with offices in Roseland and Newark, NJ. Dr Khouri's expertise is in the medical, laser, and surgical treatments of glaucoma including Minimally Invasive Glaucoma Surgery (MIGS) like the iSTENT micro-shunt, iStent inject, XEN Gel implant, and KDB Goniotomy.

The glaucoma service provides specialized glaucoma care for patients with complex eye diseases through collaborations with colleagues at the largest university academic referral practice in New Jersey (The Institute of Ophthalmology & Visual Science includes faculty teams that are specialized in collaborative care of patients with glaucoma, retina, cornea, uvietis, neuro-ophthalmology, and pediatric eye diseases).

Patient Care Resources

New Jersey's largest multidisciplinary academic university based ophthalmic consultant group- Glaucoma, Retina, Cornea, Plastics, Pediatric Ophthalmology, neuro-ophthalmology

Glaucoma Diagnostic Laboratory

Center for Clinical Trials & Research

Glaucoma expertise

Scientific Contributions

American Academy of Ophthalmology

Dr Khouri chaired the course on managing the challenges of uveitic glaucoma with national and international ophthalmology experts, Chicago, Oct 2016

MIGS surgery course, Chicago 2018

Glaucoma Subspecialty Day Faculty, 2018

Leadership Development Program, 2018

Glaucoma Subspecialty Day faculty, San Francisco, 2019

American Glaucoma Society European Glaucoma Society

Presented on additivity of fixed combination to prostaglandins therapy, CA 2017

Glaucoma tube shunt surgery, NY 2018

MIGS after glaucoma lasers, San Francisco, 2019

 The first Telemedicine Glaucoma symposium  included Drs Khouri, Pasquale and Song (USA), Damji (Canada), Czech Republic, June 2016

World Glaucoma Association

Dr Khouri chairs a scientific course with Drs from Singapore, UK and the USA on resident performed glaucoma surgery, Hong Kong, 2015.

Symposium on glaucoma surgery, Helsinki, Finland 2017

Wet Lab instruction in Minimally Invasive Glaucoma Surgery, Finland 2017

Functional testing for glaucoma, Melbourne, Australia, 2019

New Jersey Academy of Ophthalmology

Annual meeting co-sponsored with the state society leadership on advocacy and advancement of Ophthalmology in New Jersey. Dr Khouri serves on the Board of the NJ Ophthalmology Society 

Nominated to the American Academy of Ophthalmology Leadership Development Program, 2018

Vice President New Jersey Academy of Ophthalmology 2019

Association for Research in Vision & Ophthalmology

More than 100 scientific research abstracts and presentations (glaucoma surgery, laser treatment, diagnostics and imaging, resident education, Telemedicine and Teleglaucoma- among other contibutions). Dr Khouri mentors medical students and resident physicians in glaucoma research- Seattle, 2014, Denver, 2015, Chicago 2016, Baltimore, 2017, Hawaii 2018, Vancouver, 2019

International Society for Glaucoma Sugery

Symposia on optic nerve imaging, Tele-Glaucoma, glaucoma filtering surgery and management of glaucoma surgical complications, Oman 2016.

Long term efficacy of Microinvasive Glaucoma Surgery, Montreal 2018

Teaching & Research

Resident education at New Jersey Medical School

Resident Education & Innovative Research

Teaching: Dr Khouri serves as the director of resident education at the Institute of Ophthalmology & Visual Science. Dr Khouri is an active member of the American Academy of Ophthalmology and the World Glaucoma Association and chairs educational activities at national and international scientific meetings.  

Research: Together with a team of researchers Dr Khouri supervises innovative  glaucoma and telemedicine research with medical students and research associates. Ongoing research at Dr Khouri's Glaucoma Lab focuses on improving outcomes of treatments for glaucoma as well as studying new classes of medications, and novel drug delivery methods. Translational research in imaging aims at improving detection of glaucoma during ocular screening and tele-Glaucoma.

Find out more- New Medication for Glaucoma Treatment

Research Breakthroughs


Sharing the big news at the American Glaucoma Society 2018

Once-daily netarsudil 0.02% vs twice-daily timolol maleate 0.5% in ocular hypertension or open-angle glaucoma, the ROCKET-4 study


Albert Khouri, MD, Newark, NJ
Jason Bacharach, MD, North Bay Eye Associates, Inc., Petaluma, CA, United States
Richard A. Lewis, MD, Sacramento Eye Consultants, Sacramento, CA, United States
Dale Usner, PhD
Puiwah Braswell, PMP, Aerie Pharmaceuticals, Inc., Irvine, CA, United States
Nancy Ramirez, MS, Bedminster, New Jersey
Casey Kopczynski, PhD, Aerie Pharmaceuticals, Durham, NC, United States
Theresa GH. Heah, MD, Aerie Pharmaceuticals, Bedminster, NJ, United States


Netarsudil, a ROCK/NET inhibitor, lowers intraocular pressure (IOP) primarily by increasing trabecular outflow.1 In prior phase 3 trials, once-daily (QD) netarsudil 0.02% exhibited clinically significant IOP lowering in patients with elevated IOP.2 We summarize 6-month data from the phase 3 ROCKET-4 study.


ROCKET-4 (NCT02558374) was a double-masked, randomized trial in patients with unmedicated IOP >20 and <30 mmHg at 8:00 AM and >17 and <30 mmHg at 10:00 AM and 4:00 PM administered QD (PM) netarsudil 0.02% or twice-daily (BID) timolol maleate 0.5% for 6 months. Mean IOP was measured at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and months 3–6. The primary efficacy endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3 in patients with baseline IOP <25 mmHg (per-protocol population). Adverse events (AEs) were recorded to month 6.


In total, 186 patients from each arm were included in the primary analysis at baseline. Mean baseline IOP in the primary efficacy population was similar between treatment arms. QD netarsudil met the primary endpoint of noninferiority to BID timolol at all time points up to month 3; mean diurnal IOP through month 3 was 16.8–17.2 mmHg for netarsudil and 16.9–17.1 mmHg for timolol. The IOP-lowering efficacy of QD netarsudil remained within the noninferiority range of BID timolol at all time points over months 4–6. Noninferiority was also seen in patients with baseline IOP <27 mmHg or <30 mmHg. The most frequent AE was conjunctival hyperemia, which was reported in 48% of netarsudil-treated patients and graded as mild in 77% of those affected. Other ocular AEs in ROCKET-4 were comparable to those reported in prior netarsudil trials.2 No treatment-related serious AE was reported for netarsudil. Significant reductions in mean heart rate of up to 3 bpm were seen for timolol (p<0.0001).


In ROCKET-4, QD netarsudil was noninferior to BID timolol in patients with baseline IOP <25 mmHg over 3 months (primary analysis). In this final analysis, netarsudil demonstrated a consistent level of IOP lowering across all baseline IOPs that was durable over 6 months.


QD netarsudil has demonstrated consistent and sustained IOP lowering in 3 phase 3 trials, with tolerable ocular safety.

Dr Khouri Offices & Appointments

Roseland Office

556 Eagle Rock Ave, Suite 206

Roseland, NJ 07068

Newark Offices

Rutgers Doctors Office Center

Institute of Ophthalmology & Visual Science

90 Bergen St, Suite 6100

Newark, NJ 07103

NJ Glaucoma

Doctors Office Center University, 90 Bergen St, Newark, New Jersey 07103, United States

(973) 972-2065


Monday - Friday: 8am - 5pm

Saturday: Closed

Sunday: Closed

NJ Glaucoma Channel

Expertise in the repair of glaucoma related complications. In this case- a glaucoma drain is exposed predisposing a patient to unacceptable risks of infection. The area is repaired using eye bank cornea tissue. 

Albert S Khouri, MD

Expertise in the repair of glaucoma related complications. In this case- a glaucoma drain is exposed predisposing a patient to unacceptable risks of infection. The area is repaired using eye bank cornea tissue.